C3 glomerulopathy (C3G) is a prototypic complement-mediated kidney disease. Rapidly
progressive forms of C3G usually respond poorly to conventional treatments. We report on …

Abstract C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal
immunoglobulin deposition caused by alternative complement pathway dysregulation …

Background Cases reports and small series of patients with C3 glomerulopathy have
reported variable efficacy of eculizumab. Study Design Case series of C3 glomerulopathy …

Abstract Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with
grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well …

C3 glomerulopathy (C3G) is a newly defined clinical entity comprising glomerular lesions
with predominant C3 staining. Under this definition are now included membranoproliferative …

Eculizumab might benefit C3 glomerulopathies mediated by dysregulation of the alternative
complement pathway. Here, we report renal biopsy findings before and after eculizumab …

Background Eculizumab may be used to treat C3-glomerulopathy (C3G), a rare but severe
glomerular disease. Diagnosis and Treatment Patients 1, 2 and 3 were diagnosed with …

Background Hyperactivity of the alternative complement pathway is the principle defect in
C3 glomerulopathies (C3G). Eculizumab, a monoclonal antibody that binds C5 to prevent …

Anticellular immune suppression and plasma therapy have limited efficacy in C3G. Data
suggest that eculizumab may ameliorate disease in some C3G patients. The limited, recently …

Abstract C3 glomerulopathy (C3G) is a clinicopathologic entity secondary to dysregulation of
the alternative complement pathway in plasma and the glomerular microenvironment. The …